Rofecoxib, Merck, and the FDA.
Wolfe
M Michael
MM
D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000266:history; D017277:Drug Approval / Q000266:history; D004347:Drug Interactions; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000266:history; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000266:history; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects / Q000266:history; D013449:Sulfonamides / Q000009:adverse effects / Q000266:history; D013450:Sulfones / Q000009:adverse effects* / Q000266:history; D014481:United States; D014486:United States Food and Drug Administration
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D010975:Platelet Aggregation Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib; D001241:Aspirin